Atrial Fibrillation

The Business Cocktail

Anti-coagulants, API Business Opportunity, Articles, Atrial Fibrillation, Business Consultant, Pharma Consultant

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric...

Read More

Anticoagulants (VTE & AF) Therapeutics Market

Anti-coagulants, Atrial Fibrillation, Business Consultant, CVS Indications, Uncategorized, Venous Thromboembolism

The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020...

Read More

Anticoagulants-Market Insights; Drugs Sales Forecast (VTE & AF)

Anti-coagulants, Atrial Fibrillation, new therapeutic target, Specialized Reports, Venous Thromboembolism

According to DelveInsight researchers, the Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is...

Read More
Close